NeoGenomics (NASDAQ:NEO) will be announcing its earnings results before the market opens on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.04 per share for the quarter.
Shares of NeoGenomics (NASDAQ:NEO) opened at $7.35 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.99 and a current ratio of 2.14. NeoGenomics has a 1 year low of $7.08 and a 1 year high of $11.63. The firm has a market capitalization of $591.01, a P/E ratio of -21.00, a P/E/G ratio of 2.93 and a beta of 0.57.
Several equities research analysts recently weighed in on NEO shares. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Scotiabank set a $22.00 price objective on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Janney Montgomery Scott reiterated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. BidaskClub cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Royal Bank of Canada set a $23.00 price objective on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $15.83.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/neogenomics-neo-set-to-announce-quarterly-earnings-on-wednesday.html.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.